{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:53:24Z","timestamp":1783662804687,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,22]]},"DOI":"10.7759\/cureus.99818","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:54:31Z","timestamp":1766400871000},"source":"Crossref","is-referenced-by-count":1,"title":["The Impact of Direct Oral Anticoagulants vs. Warfarin on Stroke Prevention in Elderly Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Shakeel","family":"Majid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brahmaiahchari","family":"Rangachari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Okata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olive","family":"Kyaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashim","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marium","family":"Abid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Atrial fibrillation: the current epidemic","volume":"14","author":"Morillo CA","year":"2017","unstructured":"Morillo CA, Banerjee A, Perel P, Wood D, Jouven X. Atrial fibrillation: the current epidemic. J Geriatr Cardiol. 2017, 14:195-203.","journal-title":"J Geriatr Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13070","article-title":"Epidemiology of atrial fibrillation","volume":"72","author":"Zulkifly H","year":"2018","unstructured":"Zulkifly H, Lip GY, Lane DA. Epidemiology of atrial fibrillation. Int J Clin Pract. 2018, 72:e13070. 10.1111\/ijcp.13070","journal-title":"Int J Clin Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00175","article-title":"Atrial fibrillation in older people: concepts and controversies","volume":"6","author":"Zathar Z","year":"2019","unstructured":"Zathar Z, Karunatilleke A, Fawzy AM, Lip GY. Atrial fibrillation in older people: concepts and controversies. Front Med (Lausanne). 2019, 6:175. 10.3389\/fmed.2019.00175","journal-title":"Front Med (Lausanne)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/joa3.12580","article-title":"Atrial fibrillation in the elderly population: challenges and management considerations","volume":"37","author":"Salih M","year":"2021","unstructured":"Salih M, Abdel-Hafez O, Ibrahim R, Nair R. Atrial fibrillation in the elderly population: challenges and management considerations. J Arrhythm. 2021, 37:912-21. 10.1002\/joa3.12580","journal-title":"J Arrhythm"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.2099","article-title":"Clinical effectiveness of direct oral anticoagulants vs warfarin in older patients with atrial fibrillation and ischemic stroke: findings from the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study","volume":"76","author":"Xian Y","year":"2019","unstructured":"Xian Y, Xu H, O'Brien EC, et al.. Clinical effectiveness of direct oral anticoagulants vs warfarin in older patients with atrial fibrillation and ischemic stroke: findings from the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study. JAMA Neurol. 2019, 76:1192-202. 10.1001\/jamaneurol.2019.2099","journal-title":"JAMA Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S84210","article-title":"New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events","volume":"11","author":"Mekaj YH","year":"2015","unstructured":"Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015, 11:967-77. 10.2147\/TCRM.S84210","journal-title":"Ther Clin Risk Manag"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/2396987319841187","article-title":"Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: a European Stroke Organisation guideline","volume":"4","author":"Klijn CJ","year":"2019","unstructured":"Klijn CJ, Paciaroni M, Berge E, et al.. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: a European Stroke Organisation guideline. Eur Stroke J. 2019, 4:198-223. 10.1177\/2396987319841187","journal-title":"Eur Stroke J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S83664","article-title":"Managing atrial fibrillation in the very elderly patient: challenges and solutions","volume":"11","author":"Karamichalakis N","year":"2015","unstructured":"Karamichalakis N, Letsas KP, Vlachos K, Georgopoulos S, Bakalakos A, Efremidis M, Sideris A. Managing atrial fibrillation in the very elderly patient: challenges and solutions. Vasc Health Risk Manag. 2015, 11:555-62. 10.2147\/VHRM.S83664","journal-title":"Vasc Health Risk Manag"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5301\/heartint.5000230","article-title":"Atrial fibrillation management in older heart failure patients: a complex clinical problem","volume":"11","author":"Pulignano G","year":"2016","unstructured":"Pulignano G, Del Sindaco D, Tinti MD, Tolone S, Minardi G, Lax A, Uguccioni M. Atrial fibrillation management in older heart failure patients: a complex clinical problem. Heart Int. 2016, 11:e41-9. 10.5301\/heartint.5000230","journal-title":"Heart Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k2505","article-title":"Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care","volume":"362","author":"Vinogradova Y","year":"2018","unstructured":"Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018, 362:k2505. 10.1136\/bmj.k2505","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02333-9","article-title":"Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review","volume":"40","author":"Ballestri S","year":"2023","unstructured":"Ballestri S, Romagnoli E, Arioli D, et al.. Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review. Adv Ther. 2023, 40:41-66. 10.1007\/s12325-022-02333-9","journal-title":"Adv Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013267","article-title":"Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis","volume":"132","author":"Sharma M","year":"2015","unstructured":"Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation. 2015, 132:194-204. 10.1161\/CIRCULATIONAHA.114.013267","journal-title":"Circulation"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.907197","article-title":"Effectiveness and safety of DOACs vs. warfarin in patients with atrial fibrillation and frailty: a systematic review and meta-analysis","volume":"9","author":"Zeng S","year":"2022","unstructured":"Zeng S, Zheng Y, Jiang J, Ma J, Zhu W, Cai X. Effectiveness and safety of DOACs vs. warfarin in patients with atrial fibrillation and frailty: a systematic review and meta-analysis. Front Cardiovasc Med. 2022, 9:907197. 10.3389\/fcvm.2022.907197","journal-title":"Front Cardiovasc Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/2327-6924.12494","article-title":"Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation","volume":"29","author":"Oertel LB","year":"2017","unstructured":"Oertel LB, Fogerty AE. Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation. J Am Assoc Nurse Pract. 2017, 29:551-61. 10.1002\/2327-6924.12494","journal-title":"J Am Assoc Nurse Pract"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.15420\/ecr.2024.17","article-title":"Direct oral anticoagulant use in older adults with atrial fibrillation: challenges and solutions","volume":"20","author":"Bhandari M","year":"2025","unstructured":"Bhandari M, Pradhan A, Vishwakarma P, Di Renzo L, Iellamo F, Ali W, Perrone MA. Direct oral anticoagulant use in older adults with atrial fibrillation: challenges and solutions. Eur Cardiol. 2025, 20:e03.","journal-title":"Eur Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/2042098618774498","article-title":"Dosing challenges with direct oral anticoagulants in the elderly: a retrospective analysis","volume":"9","author":"Fava JP","year":"2018","unstructured":"Fava JP, Starr KM, Ratz D, Clemente JL. Dosing challenges with direct oral anticoagulants in the elderly: a retrospective analysis. Ther Adv Drug Saf. 2018, 9:405-14. 10.1177\/2042098618774498","journal-title":"Ther Adv Drug Saf"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32439-9","article-title":"Direct oral anticoagulants: evidence and unresolved issues","volume":"396","author":"Chan N","year":"2020","unstructured":"Chan N, Sobieraj-Teague M, Eikelboom JW. Direct oral anticoagulants: evidence and unresolved issues. Lancet. 2020, 396:1767-76. 10.1016\/S0140-6736(20)32439-9","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.06.015","article-title":"The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application","volume":"126","author":"Minozzi S","year":"2020","unstructured":"Minozzi S, Cinquini M, Gianola S, Gonzalez-Lorenzo M, Banzi R. The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application. J Clin Epidemiol. 2020, 126:37-44. 10.1016\/j.jclinepi.2020.06.015","journal-title":"J Clin Epidemiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/jre.13405","article-title":"Risk of bias evaluation of cross-sectional studies: adaptation of the Newcastle-Ottawa Scale","author":"Carra MC","year":"2025","unstructured":"Carra MC, Romandini P, Romandini M. Risk of bias evaluation of cross-sectional studies: adaptation of the Newcastle-Ottawa Scale. J Periodontal Res. 2025, 10.1111\/jre.13405","journal-title":"J Periodontal Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2019.01.009","article-title":"Effects of dietary patterns and low protein intake on sarcopenia risk in the very old: the Newcastle 85+ study","volume":"39","author":"Granic A","year":"2020","unstructured":"Granic A, Mendon\u00e7a N, Sayer AA, et al.. Effects of dietary patterns and low protein intake on sarcopenia risk in the very old: the Newcastle 85+ study. Clin Nutr. 2020, 39:166-73. 10.1016\/j.clnu.2019.01.009","journal-title":"Clin Nutr"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom JW","year":"2011","unstructured":"Eikelboom JW, Wallentin L, Connolly SJ, et al.. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011, 123:2363-72. 10.1161\/CIRCULATIONAHA.110.004747","journal-title":"Circulation"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu046","article-title":"Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial","volume":"35","author":"Halvorsen S","year":"2014","unstructured":"Halvorsen S, Atar D, Yang H, et al.. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014, 35:1864-72. 10.1093\/eurheartj\/ehu046","journal-title":"Eur Heart J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005008","article-title":"Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)","volume":"130","author":"Halperin JL","year":"2014","unstructured":"Halperin JL, Hankey GJ, Wojdyla DM, et al.. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014, 130:138-46. 10.1161\/CIRCULATIONAHA.113.005008","journal-title":"Circulation"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.012061","article-title":"Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation","volume":"131","author":"Graham DJ","year":"2015","unstructured":"Graham DJ, Reichman ME, Wernecke M, et al.. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015, 131:157-64. 10.1161\/CIRCULATIONAHA.114.012061","journal-title":"Circulation"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003432","article-title":"Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial","volume":"5","author":"Kato ET","year":"2016","unstructured":"Kato ET, Giugliano RP, Ruff CT, et al.. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2016, 5:10.1161\/JAHA.116.003432","journal-title":"J Am Heart Assoc"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.06.034","article-title":"Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis","volume":"68","author":"Steffel J","year":"2016","unstructured":"Steffel J, Giugliano RP, Braunwald E, et al.. Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis. J Am Coll Cardiol. 2016, 68:1169-78. 10.1016\/j.jacc.2016.06.034","journal-title":"J Am Coll Cardiol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-019-01838-5","article-title":"Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population","volume":"48","author":"Amin A","year":"2019","unstructured":"Amin A, Keshishian A, Dina O, et al.. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population. J Thromb Thrombolysis. 2019, 48:240-9. 10.1007\/s11239-019-01838-5","journal-title":"J Thromb Thrombolysis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.120.029541","article-title":"Comparative effectiveness of rivaroxaban, apixaban, and warfarin in atrial fibrillation patients with polypharmacy","volume":"51","author":"Mentias A","year":"2020","unstructured":"Mentias A, Heller E, Vaughan Sarrazin M. Comparative effectiveness of rivaroxaban, apixaban, and warfarin in atrial fibrillation patients with polypharmacy. Stroke. 2020, 51:2076-86. 10.1161\/STROKEAHA.120.029541","journal-title":"Stroke"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.4086","article-title":"Comparative effectiveness and safety of oral anticoagulants by dementia status in older patients with atrial fibrillation","volume":"6","author":"Lin KJ","year":"2023","unstructured":"Lin KJ, Singer DE, Bykov K, Bessette LG, Mastrorilli JM, Cervone A, Kim DH. Comparative effectiveness and safety of oral anticoagulants by dementia status in older patients with atrial fibrillation. JAMA Netw Open. 2023, 6:e234086. 10.1001\/jamanetworkopen.2023.4086","journal-title":"JAMA Netw Open"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.036832","article-title":"Outcomes and disease management in patients with atrial fibrillation \u226580\u2009years: data from a consecutive 11-year real-world registry","volume":"14","author":"Yildirim M","year":"2025","unstructured":"Yildirim M, Milles BR, Hund H, et al.. Outcomes and disease management in patients with atrial fibrillation \u226580\u2009years: data from a consecutive 11-year real-world registry. J Am Heart Assoc. 2025, 14:e036832. 10.1161\/JAHA.124.036832","journal-title":"J Am Heart Assoc"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.2165","article-title":"The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons","volume":"7","author":"Nejadghaderi SA","year":"2024","unstructured":"Nejadghaderi SA, Balibegloo M, Rezaei N. The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons. Health Sci Rep. 2024, 7:e2165. 10.1002\/hsr2.2165","journal-title":"Health Sci Rep"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.13105\/wjma.v5.i4.80","article-title":"Assessing the quality of studies in meta-analyses: advantages and limitations of the Newcastle Ottawa Scale","volume":"5","author":"Luchini C","year":"2017","unstructured":"Luchini C, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analyses: advantages and limitations of the Newcastle Ottawa Scale. World Journal of Meta-Analysis. 2017, 5:80-84. 10.13105\/wjma.v5.i4.80","journal-title":"World Journal of Meta-Analysis"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-018-4425-7","article-title":"Empirical comparison of publication bias tests in meta-analysis","volume":"33","author":"Lin L","year":"2018","unstructured":"Lin L, Chu H, Murad MH, Hong C, Qu Z, Cole SR, Chen Y. Empirical comparison of publication bias tests in meta-analysis. J Gen Intern Med. 2018, 33:1260-7. 10.1007\/s11606-018-4425-7","journal-title":"J Gen Intern Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2017.10.07","article-title":"Rainforest plots for the presentation of patient-subgroup analysis in clinical trials","volume":"5","author":"Zhang Z","year":"2017","unstructured":"Zhang Z, Kossmeier M, Tran US, Voracek M, Zhang H. Rainforest plots for the presentation of patient-subgroup analysis in clinical trials. Ann Transl Med. 2017, 5:485. 10.21037\/atm.2017.10.07","journal-title":"Ann Transl Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1590\/S1677-5538.IBJU.2023.9911","article-title":"Systematic review and metanalysis in urology: how to interpret the forest plot","volume":"49","author":"Favorito LA","year":"2023","unstructured":"Favorito LA. Systematic review and metanalysis in urology: how to interpret the forest plot. Int Braz J Urol. 2023, 49:775-8. 10.1590\/S1677-5538.IBJU.2023.9911","journal-title":"Int Braz J Urol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2020.02.015","article-title":"Methods and challenges for assessing heterogeneity","volume":"88","author":"Feczko E","year":"2020","unstructured":"Feczko E, Fair DA. Methods and challenges for assessing heterogeneity. Biol Psychiatry. 2020, 88:9-17. 10.1016\/j.biopsych.2020.02.015","journal-title":"Biol Psychiatry"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201411-2125CP","article-title":"Implications of heterogeneity of treatment effect for reporting and analysis of randomized trials in critical care","volume":"192","author":"Iwashyna TJ","year":"2015","unstructured":"Iwashyna TJ, Burke JF, Sussman JB, Prescott HC, Hayward RA, Angus DC. Implications of heterogeneity of treatment effect for reporting and analysis of randomized trials in critical care. Am J Respir Crit Care Med. 2015, 192:1045-51. 10.1164\/rccm.201411-2125CP","journal-title":"Am J Respir Crit Care Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer","volume":"2","author":"McLaughlin J","year":"2016","unstructured":"McLaughlin J, Han G, Schalper KA, et al.. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2016, 2:46-54. 10.1001\/jamaoncol.2015.3638","journal-title":"JAMA Oncol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cegh.2018.05.005","article-title":"Interpretation of subgroup analyses in systematic reviews: a tutorial","volume":"7","author":"Richardson M","year":"2019","unstructured":"Richardson M, Garner P, Donegan S. Interpretation of subgroup analyses in systematic reviews: a tutorial. Clin Epidemiol Glob Health. 2019, 7:192-8. 10.1016\/j.cegh.2018.05.005","journal-title":"Clin Epidemiol Glob Health"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.12.008","article-title":"Statistical considerations for subgroup analyses","volume":"16","author":"Wang X","year":"2021","unstructured":"Wang X, Piantadosi S, Le-Rademacher J, Mandrekar SJ. Statistical considerations for subgroup analyses. J Thorac Oncol. 2021, 16:375-80. 10.1016\/j.jtho.2020.12.008","journal-title":"J Thorac Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcab076","article-title":"Stroke prevention with direct oral anticoagulants in high-risk elderly atrial fibrillation patients at increased bleeding risk","volume":"8","author":"Chao TF","year":"2022","unstructured":"Chao TF, Chan YH, Chiang CE, et al.. Stroke prevention with direct oral anticoagulants in high-risk elderly atrial fibrillation patients at increased bleeding risk. Eur Heart J Qual Care Clin Outcomes. 2022, 8:730-8. 10.1093\/ehjqcco\/qcab076","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00107","article-title":"Efficacy and safety of direct oral anticoagulants in elderly patients with atrial fibrillation: a network meta-analysis","volume":"7","author":"Deng K","year":"2020","unstructured":"Deng K, Cheng J, Rao S, Xu H, Li L, Gao Y. Efficacy and safety of direct oral anticoagulants in elderly patients with atrial fibrillation: a network meta-analysis. Front Med (Lausanne). 2020, 7:107. 10.3389\/fmed.2020.00107","journal-title":"Front Med (Lausanne)"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000703","article-title":"Effects of oral anticoagulants on patients with atrial fibrillation aged 90 years and older: comparison among direct oral anticoagulant, warfarin anticoagulant, and nonanticoagulation","volume":"74","author":"Yamaji H","year":"2019","unstructured":"Yamaji H, Higashiya S, Murakami T, et al.. Effects of oral anticoagulants on patients with atrial fibrillation aged 90 years and older: comparison among direct oral anticoagulant, warfarin anticoagulant, and nonanticoagulation. J Cardiovasc Pharmacol. 2019, 74:246-54. 10.1097\/FJC.0000000000000703","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02067-5","article-title":"Prescribing of direct oral anticoagulants and warfarin to older people with atrial fibrillation in UK general practice: a cohort study","volume":"19","author":"Mitchell A","year":"2021","unstructured":"Mitchell A, Snowball J, Welsh TJ, Watson MC, McGrogan A. Prescribing of direct oral anticoagulants and warfarin to older people with atrial fibrillation in UK general practice: a cohort study. BMC Med. 2021, 19:189. 10.1186\/s12916-021-02067-5","journal-title":"BMC Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030380","article-title":"Efficacy and safety of direct oral anticoagulants for stroke prevention in older patients with atrial fibrillation: a network meta-analysis of randomized controlled trials","volume":"12","author":"Lin DS","year":"2023","unstructured":"Lin DS, Lo HY, Huang KC, Lin TT, Lee JK. Efficacy and safety of direct oral anticoagulants for stroke prevention in older patients with atrial fibrillation: a network meta-analysis of randomized controlled trials. J Am Heart Assoc. 2023, 12:e030380. 10.1161\/JAHA.123.030380","journal-title":"J Am Heart Assoc"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/439423-the-impact-of-direct-oral-anticoagulants-vs-warfarin-on-stroke-prevention-in-elderly-patients-with-atrial-fibrillation-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:54:32Z","timestamp":1766400872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/439423-the-impact-of-direct-oral-anticoagulants-vs-warfarin-on-stroke-prevention-in-elderly-patients-with-atrial-fibrillation-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":45,"URL":"https:\/\/doi.org\/10.7759\/cureus.99818","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,22]]}}}